Quality of Life and Pain Relief during Treatment with Calcitriol and Docetaxel in Symptomatic Metastatic Androgen-Independent Prostate Carcinoma

Tomasz M. Beer, Kristine M. Eilers, Mark Garzotto, Yi Ching Hsieh, Motomi Mori

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

BACKGROUND. The current study evaluated the analgesic activity and impact on quality of life (QOL) of a new chemotherapy regimen of calcitriol and docetaxel in men with androgen-independent prostate carcinoma. METHODS. Analgesic response was defined as a 2-point reduction on the Present Pain Intensity (PPI) scale (or compete relief if baseline PPI was 1) without an increase in analgesic use or a 50% decrease in analgesic medication use without an increase in pain, maintained for ≥4 weeks. Pain, pain medication consumption, and QOL (measured by the European Organization for Research and Treatment of Cancer QLQ-C30) were evaluated every 4 weeks. RESULTS. Treatment resulted in an analgesic response in 14 of 29 evaluable patients (48%; 95% confidence interval [95% CI], 30-67%). The median time to symptomatic progression in the 14 patients who met criteria for analgesic response was 41 weeks (95% CI, 26-56 weeks). Worsening in physical and role functioning, fatigue, appetite, and global health status and improvement in constipation were detected using the QLQ-C30 QOL questionnaire. CONCLUSIONS. Significant analgesic activity was demonstrated, although worsening in several QOL domains was observed in a patient population with relatively low pain intensity (median PPI, 2).

Original languageEnglish (US)
Pages (from-to)758-763
Number of pages6
JournalCancer
Volume100
Issue number4
DOIs
StatePublished - Feb 15 2004

Keywords

  • Calcitriol
  • Docetaxel
  • Prostate carcinoma
  • Quality of life

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Quality of Life and Pain Relief during Treatment with Calcitriol and Docetaxel in Symptomatic Metastatic Androgen-Independent Prostate Carcinoma'. Together they form a unique fingerprint.

  • Cite this